Anavex Life Sciences Corp (AVXL)

[Investor2014]

Agree. It seems absurd not to take the time run the pre-specified subgroups KEM Analysis before releasing results. As I understand the Anavex Precision Medicine approach is all about proving the data driven biomarker hypothesis from the P2a AD data.

If that hypothesis proves out strongly (stat sig) in the current trials I consider that a great success, which significantly increases the chances of approval from pivotal trials with the right medicine for the right patients.

NTRP and BIIB ran posthoc subgroup analysis not to be compared with pre-specified analysis.